Talphera, Inc. (NASDAQ:TLPH) Short Interest Down 15.4% in February

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 75,400 shares, a decrease of 15.4% from the January 31st total of 89,100 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily volume of 94,800 shares, the short-interest ratio is presently 0.8 days.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Talphera in a research note on Tuesday, January 21st. RODMAN&RENSHAW upgraded shares of Talphera to a “strong-buy” rating in a research note on Tuesday, January 28th. Maxim Group upgraded shares of Talphera to a “strong-buy” rating in a research report on Friday, November 8th. Finally, Rodman & Renshaw assumed coverage on shares of Talphera in a report on Tuesday, January 28th. They issued a “buy” rating and a $4.00 target price on the stock.

Hedge Funds Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Rosalind Advisors Inc. bought a new position in Talphera, Inc. (NASDAQ:TLPH) in the 3rd quarter, according to its most recent disclosure with the SEC. The firm bought 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera accounts for approximately 0.4% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 25th largest holding. Rosalind Advisors Inc. owned 4.47% of Talphera as of its most recent SEC filing. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Talphera Stock Performance

Shares of TLPH stock opened at $0.55 on Thursday. The company has a 50-day simple moving average of $0.61 and a two-hundred day simple moving average of $0.76. Talphera has a 52-week low of $0.50 and a 52-week high of $1.31. The company has a market capitalization of $9.28 million, a price-to-earnings ratio of -0.79 and a beta of 0.29.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.